PUBLISHER: Grand View Research | PRODUCT CODE: 1869728
PUBLISHER: Grand View Research | PRODUCT CODE: 1869728
The global bioprocess automation market size was estimated at USD 7.76 billion in 2024 and is projected to reach USD 22.41 billion by 2033, growing at a CAGR of 12.67% from 2025 to 2033, driven by rising demand for biologics, advancements in AI and robotics, and the need for regulatory compliance and efficiency.
Rising Demand for Biologics
The rising demand for biologics is among the most significant drivers of the bioprocess automation industry. Over the past decade, there has been a sharp increase in the development and use of monoclonal antibodies, vaccines, gene therapies, and other biologic products due to their effectiveness in treating complex diseases, including cancer, autoimmune disorders, and rare genetic conditions. For these biologics to remain effective and to maintain high quality, manufacturing procedures must be extremely controlled, scalable, and precise. There is a significant need for fully automated bioprocess solutions because traditional manual or semi-automated production methods are frequently labor-intensive, prone to mistakes, and inadequate to meet the expanding market demand.
The need for bioprocess automation is anticipated to increase as the world's healthcare system depends more on biology for novel treatments, making it an essential part of contemporary pharmaceutical production. Automation in bioprocessing allows manufacturers to optimize production workflows, improve consistency, and increase throughput without compromising quality. Biopharmaceutical companies can produce larger biologics with reduced variability, faster turnaround times, and lower operational costs by integrating robotics, AI, and advanced monitoring systems.
Need for Efficiency and Cost Reduction
The need for cost and efficiency reduction largely drives the market for bioprocess automation. Manufacturing biopharmaceuticals is a complicated and resource-intensive process that frequently requires highly qualified staff, careful observation, and strict protocol adherence. Batch failures, inconsistent products, and higher production costs can result from labor-intensive, human error-prone manual or semi-automated processes. By implementing automated systems, businesses can increase productivity, decrease reliance on manual labor, and minimize errors, guaranteeing more consistent and dependable results across production batches.
Automation increases productivity, drastically reduces operating costs, and improves reliability. Manufacturers can more effectively meet growing market demand thanks to automated bioprocessing systems' ability to run continuously with little downtime, optimize resource usage, and speed up production cycles. In an increasingly cost-sensitive healthcare environment, the ability to produce high-quality biologics at a lower cost also helps businesses stay competitive. As a result, the need for cost-effectiveness and operational efficiency keeps driving global investments in bioprocess automation technologies.
Global Bioprocess Automation Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global bioprocess automation market report based on product & service, process stage, end use, and region: